SUMO2 — Small Ubiquitin-Like Modifier 2

SUMO2 — Small Ubiquitin-Like Modifier 2

Overview

Sumo2 — Small Ubiquitin Like Modifier 2 plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

Introduction

SUMO2 — Small Ubiquitin-Like Modifier 2

Overview

Sumo2 — Small Ubiquitin Like Modifier 2 plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

Introduction

SUMO2 (Small Ubiquitin-Like Modifier 2) is a ubiquitin-like protein that plays critical roles in post-translational modification through SUMOylation. Unlike classical ubiquitination which typically targets proteins for degradation, SUMOylation modulates protein function, localization, stability, and protein-protein interactions. SUMO2 is the most abundant SUMO paralog in mammalian cells and is particularly crucial for stress-induced SUMOylation responses. This page provides comprehensive information about SUMO2's structure, function, and role in neurodegenerative diseases.

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">SUMO2 — Small Ubiquitin-Like Modifier 2</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>SUMO2</td></tr>
<tr><td><strong>Full Name</strong></td><td>Small Ubiquitin-Like Modifier 2</td></tr>
<tr><td><strong>Chromosome</strong></td><td>17q25.1</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[6613](https://www.ncbi.nlm.nih.gov/gene/6613)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000193900</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P61956](https://www.uniprot.org/uniprot/P61956)</td></tr>
<tr><td><strong>Protein Length</strong></td><td>95 amino acids</td></tr>
<tr><td><strong>Protein Family</strong></td><td>SUMO family (ubiquitin-like)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Amyotrophic Lateral Sclerosis</td></tr>
</table>
</div>

SUMOylation Overview

SUMOylation is a reversible post-translational modification involving covalent attachment of SUMO proteins to lysine residues on target proteins. This process is catalyzed by:

• E1 activating enzyme: SAE1/UBA2 (SUMO-activating enzyme)
• E2 conjugating enzyme: UBC9 (SUMO-conjugating enzyme)
• E3 ligases: PIAS family, RanBP2, CBX4

| Enzyme | Function | Substrate Preference |
|--------|----------|----------------------|
| SENP1 | SUMO maturation, deconjugation | SUMO1, SUMO2, SUMO3 |
| SENP2 | Nuclear envelope functions | SUMO1, SUMO2, SUMO3 |
| SENP3 | Mitochondrial/ nucleolar | SUMO2, SUMO3 |
| SENP5 | Mitochondrial | SUMO2, SUMO3 |
| SENP6 | Poly-SUMO chain editing | SUMO2, SUMO3 |
| SENP7 | Poly-SUMO chain editing | SUMO2, SUMO3 |

SUMO2 Structure and Biochemistry

SUMO2 is a 95-amino acid protein (~10.5 kDa) with structural similarity to ubiquitin:

• β-grasp fold: Similar to ubiquitin tertiary structure
• C-terminal diglycine motif: Required for conjugation
• N-terminal flexible region: Contains SUMO2-specific features
• Lysine-11: Critical for poly-SUMO chain formation

SUMO1 vs SUMO2

| Feature | SUMO1 | SUMO2 |
|---------|-------|-------|
| Amino acids | 101 | 95 |
| Identity to ubiquitin | ~18% | ~20% |
| Expression level | Lower | Higher |
| Basal SUMOylation | Moderate | High |
| Stress-induced | Moderate | Very high |
| Chain formation | Limited (mainly heterotypic) | Robust (K11) |

Normal Physiological Functions

Stress Response

SUMO2 is particularly important for cellular stress responses:

• Heat shock: Rapid increase in SUMO2 conjugation
• Oxidative stress: Protective SUMOylation
• DNA damage: SUMO2-mediated repair
• Hypoxia: Adaptive SUMOylation

Protein Quality Control

SUMO2 plays essential roles in protein homeostasis:

• Targeting misfolded proteins for degradation
• Facilitating protein aggregate clearance
• Regulating [autophagy](/entities/autophagy)
• Coordinating proteostasis networks

Transcription Regulation

SUMO2 modulates gene expression through:

• Transcription factor SUMOylation
• Histone modification
• Chromatin remodeling
• Nuclear receptor regulation

Cell Cycle

SUMO2 participates in cell cycle regulation:

• Mitotic spindle assembly
• Chromosome segregation
• Kinetochore function
• Cytokinesis

DNA Repair

SUMO2 is crucial for DNA damage response:

• Recruitment of repair proteins
• Regulation of p53 activity
• Telomere maintenance
• Homologous recombination

SUMOylation in Neurodegeneration

Alzheimer's Disease (AD)

SUMO2 is heavily implicated in AD pathogenesis:

| Finding | Significance |
|---------|--------------|
| Elevated SUMO2 conjugation in AD brain | Global increase in SUMOylation |
| SUMOylated APP | Altered amyloid processing |
| SUMO and [Aβ](/proteins/amyloid-beta) overlap | Colocalization in plaques |
| UBC9 dysregulation | Altered SUMO enzyme levels |

Mechanisms

Parkinson's Disease (PD)

SUMO2 alterations in PD include:

• Increased SUMO2 conjugation in substantia nigra
• SUMOylation of [α-synuclein](/proteins/alpha-synuclein)
• Mitochondrial dysfunction via SUMO2
• DJ-1 SUMOylation (protective)

Huntington's Disease (HD)

SUMO2 plays complex roles in HD:

• Mutant [huntingtin](/proteins/huntingtin) SUMOylation
• Altered transcriptional regulation
• Mitochondrial dysfunction
• Aggregate formation

Amyotrophic Lateral Sclerosis (ALS)

In ALS:

• [TDP-43](/mechanisms/tdp-43-proteinopathy) SUMOylation abnormalities
• FUS SUMOylation
• Oxidative stress response
• RNA metabolism dysregulation

Key Signaling Pathways

SUMOylation and NF-κB

SUMO2 regulates [NF-κB](/entities/nf-kb) signaling through:

• IκBα stabilization
• NF-κB repressor complexes
• Transcriptional co-factors

SUMOylation and p53

The p53 tumor suppressor is regulated by SUMO2:

• Modulates transcriptional activity
• Affects protein stability
• Influences apoptotic function

SUMOylation and Mitochondria

SUMO2 modifies mitochondrial proteins:

• Metabolic enzymes
• Import machinery
• Dynamics proteins (fusion/fission)
• Apoptotic proteins

Therapeutic Implications

Drug Development

Targeting SUMOylation for neurodegeneration:

• SUMOylation inhibitors: Reduce pathological SUMOylation
• SENP inhibitors: Modulate SUMO deconjugation
• SUMO-specific E3 ligase modulators: Alter substrate specificity

Biomarkers

SUMOylation as a biomarker:

• Blood/CSF SUMO2 levels
• SUMO enzyme activity
• Protein SUMOylation patterns

Key Publications

[@tatham2011]: Tatham MH, Jaffray E, Vaughan OA, et al. Unique degradation signals in short-lived, long-lived, and ubiquitinated proteins. Sci Signal. 2011;4(203):ra41. PMID: 21693764(https://pubmed.ncbi.nlm.nih.gov/21693764/)

[@hay2005]: Hay RT. SUMO: a history of modification. Mol Cell. 2005;18(1):1-12. PMID: 15808504(https://pubmed.ncbi.nlm.nih.gov/15808504/)

[@mahajan1997]: Mahajan R, Delphin C, Guan T, et al. A small ubiquitin-related polypeptide involved in targeting RanGAP1 to nuclear pore complex protein RanBP2. Cell. 1997;88(1):97-107. PMID: 9019411(https://pubmed.ncbi.nlm.nih.gov/9019411/)

[@saitoh2000]: Saitoh H, Hinchey J. Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3. J Biol Chem. 2000;275(9):6252-6258. PMID: 10692421(https://pubmed.ncbi.nlm.nih.gov/10692421/)

[@yang2008]: Yang W, Sheng H, Warner DS, Paschen W. Transient global cerebral ischemia induces a prolonged increase in small ubiquitin-like modifier conjugating enzyme 1 (UBC9) and sumoylation in rat brain. Neurobiol Dis. 2008;32(1):133-144. PMID: 18638556(https://pubmed.ncbi.nlm.nih.gov/18638556/)

[@kim2019]: Kim T, Yoon BS, Letunic I, et al. Cross-species analysis of the mammalian SUMOylation system. BMC Genomics. 2019;20(1):984. PMID: 31888490(https://pubmed.ncbi.nlm.nih.gov/31888490/)

See Also

• [SUMO1 Gene](/genes/sumo1)
• [SUMO3 Gene](/genes/sumo3)
• [SUMOylation Pathway](/mechanisms/sumoylation-pathway)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Huntington's Disease](/diseases/huntingtons)
• [Protein Quality Control in Neurodegeneration](/mechanisms/protein-quality-control-network))
• [Ubiquitin-Proteasome System](/cell-types/ubiquitin-proteasome-system)

External Links

• [NCBI Gene: SUMO2](https://www.ncbi.nlm.nih.gov/gene/6613)
• [UniProt: P61956](https://www.uniprot.org/uniprot/P61956)
• [Ensembl: ENSG00000193900](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000193900)
• [SUMOplot: SUMOylation prediction](https://www.abgent.com/sumoplot)

Overview

Sumo2 — Small Ubiquitin Like Modifier 2 plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

Background

The study of Sumo2 — Small Ubiquitin Like Modifier 2 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

Pathway Diagram

The following diagram shows the key molecular relationships involving SUMO2 — Small Ubiquitin-Like Modifier 2 discovered through SciDEX knowledge graph analysis: